Pharmacokinetic analysis of pralidoxime after its intramuscular injection alone or in combination with atropine-avizafone in healthy volunteers.
OBJECTIVE
Treatment of organophosphate poisoning with pralidoxime needs to be improved. Here we have studied the pharmacokinetics of pralidoxime after its intramuscular injection alone or in combination with avizafone and atropine using an auto-injector device.


METHODS
The study was conducted in an open, randomized, single-dose, two-way, cross-over design. At each period, each subject received either intramuscular injections of pralidoxime (700 mg), or two injections of the combination: pralidoxime (350 mg), atropine (2 mg), avizafone (20 mg). Pralidoxime concentrations were quantified using a validated LC/MS-MS method. Two approaches were used to analyse these data: (i) a non-compartmental approach; and (ii) a compartmental modelling approach.


RESULTS
The injection of pralidoxime combination with atropine and avizafone provided a higher pralidoxime maximal concentration than that obtained after the injection of pralidoxime alone (out of bioequivalence range), while pralidoxime AUC values were equivalent. Pralidoxime concentrations reached their maximal value earlier after the injection of the combination. According to Akaike and to goodness of fit criteria, the best model describing the pharmacokinetics of pralidoxime was a two-compartment with a zero-order absorption model. When avizafone and atropine were injected with pralidoxime, the best model describing pralidoxime pharmacokinetics becomes a two-compartment with a first-order absorption model.


CONCLUSIONS
The two approaches, non-compartmental and compartmental, showed that the administration of avizafone and atropine with pralidoxime results in a faster absorption into the general circulation and higher maximal concentrations, compared with the administration of pralidoxime alone.
Abbara
C
C
Université d'Angers, UFR médecine, Angers cedex, F-49045, France. chadi.abbara@gmail.com
Rousseau
J M
JM
Lelièvre
B
B
Turcant
A
A
Lallement
G
G
Ferec
S
S
Bardot
I
I
Diquet
B
B
D000293:Adolescent; D000328:Adult; D001285:Atropine / Q000008:administration & dosage*; D004151:Dipeptides / Q000008:administration & dosage*; D004338:Drug Combinations; D004347:Drug Interactions; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D011220:Pralidoxime Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*
D004151:Dipeptides; D004338:Drug Combinations; D011220:Pralidoxime Compounds; C065249:pro-diazepam; D001285:Atropine; C028797:pralidoxime
Neth J Med. 2008 Apr;66(4):146-8
18424860
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Oct 15;874(1-2):42-50
18805073
Neurosci Biobehav Rev. 1993 Summer;17(2):203-15
8515903
Neurotoxicology. 1995 Spring;16(1):123-32
7603632
Epilepsy Res. 1990 Nov;7(2):105-16
2289469
Br J Pharmacol. 2009 Aug;157(8):1390-7
19681868
Neurosci Biobehav Rev. 1997 Sep;21(5):559-79
9353792
Toxicology. 2007 Apr 20;233(1-3):120-7
16979808
Neurosci Biobehav Rev. 1991 Fall;15(3):349-62
1683477
Lancet. 2008 Feb 16;371(9612):597-607
17706760
Toxicology. 2006 Aug 1;225(1):25-35
16784801
Arch Toxicol. 1992;66(4):260-6
1514924
Neurotoxicology. 1994 Winter;15(4):837-51
7715855
Fundam Clin Pharmacol. 1992;6(7):309-18
1490651
Lancet. 2008 Jun 28;371(9631):2169-70; author reply 2170-1
18586164
Br J Pharmacol. 2009 Nov;158 Suppl 1:S1-254
19883461
Neurotoxicology. 1992 Fall;13(3):557-67
1475060
Lancet. 2006 Dec 16;368(9553):2136-41
17174705